Tempest Therapeutics, Inc. (TPST)
Fuera de horario:
Tempest Therapeutics, Inc.
2000 Sierra Point Parkway
Suite 400
Brisbane, CA 94005
United States
415 798 8589
https://www.tempesttx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 17
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Stephen R. Brady J.D., LLM | CEO, President & Director | 923.24k | N/D | 1970 |
| Mr. Nicholas Maestas | VP of Strategy & Finance and Secretary | 465.43k | N/D | 1981 |
| Dr. Samuel Whiting M.D., Ph.D. | Executive VP & Chief Medical Officer | 667.65k | N/D | 1966 |
| Mr. Justin Trojanowski | Corporate Controller, Treasurer & Principal Accounting Officer | N/D | N/D | 1988 |
| Ms. Lindsay Young | Head of Human Resources | N/D | N/D | N/D |
| Dr. Sharon Sakai Ph.D., RAC | Head of Regulatory & Quality | N/D | N/D | N/D |
Descripción
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Gestión corporativa
La calificación ISS Governance QuickScore de Tempest Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
